03/08/2021 | Press release | Distributed by Public on 03/08/2021 16:49
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company's participation are as follows:
For more information or to schedule a one-on-one meeting with management, please contact your conference representative.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, please visit www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005912/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
[email protected]
Source: DiaMedica Therapeutics Inc.
Released March 8, 2021